Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Jazz Pharma Plc (NQ: JAZZ ) 101.20 +0.63 (+0.63%) Streaming Delayed Price Updated: 12:22 PM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Jazz Pharma Plc < Previous 1 2 ... 5 6 7 8 9 10 11 12 Next > 'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst August 05, 2022 Via Benzinga Where Jazz Pharmaceuticals Stands With Analysts August 04, 2022 Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: Via Benzinga Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial August 03, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga 7 Biotech Stocks to Buy for Q3 July 18, 2022 These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. Via InvestorPlace Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate May 05, 2022 Via Benzinga Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread July 15, 2022 The company just hired three new executives, likely putting a buyout in the rearview. Via Investor's Business Daily Cannabis Stocks Struggle Through Q2 2022 July 15, 2022 An overview of how cannabis stocks fared in Q2 and what investors should understand about the space. Via Talk Markets Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study July 11, 2022 Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. Via Benzinga Brazilian Fund Invests $19M In US Cannabis Stocks July 05, 2022 As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are... Via Benzinga What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder June 29, 2022 Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea... Via Benzinga Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint June 28, 2022 Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with... Via Benzinga Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity June 28, 2022 Via Benzinga Switzerland Removes Medical Marijuana Access Limitations As Demand Rises June 23, 2022 The Swiss government confirmed that it will remove limitations on medical marijuana use, starting August 1st, 2022. Via Benzinga This Pharmaceutical Company Is Moving Beyond CBD June 23, 2022 The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge... Via Benzinga Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL June 23, 2022 Thomas Wesley Pentz, better known for his artistic name, Diplo, partnered with California cannabis beverage company Leisuretown, professional skateboarder Rob Dyrdek and cannabis supply chain company... Via Benzinga 4 Analysts Have This to Say About Jazz Pharmaceuticals June 14, 2022 Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 June 14, 2022 Upgrades Via Benzinga Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research June 10, 2022 The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans. Via Benzinga North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization? June 09, 2022 The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal. Via Benzinga The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study June 07, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals May 27, 2022 The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel... Via Benzinga Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating May 17, 2022 Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level. Via Investor's Business Daily Jazz Pharmaceuticals's Return On Capital Employed Insights May 17, 2022 Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between... Via Benzinga What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval? May 11, 2022 Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. Via Benzinga Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next? May 09, 2022 Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S. Via Benzinga What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals May 05, 2022 Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Via Benzinga The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study May 05, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY May 05, 2022 Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022. Via Benzinga Jazz Pharmaceuticals: Q1 Earnings Insights May 04, 2022 Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement. Via Benzinga The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints May 04, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga < Previous 1 2 ... 5 6 7 8 9 10 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.